Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 80 Publications

18 Customer Reviews

  • CYREN does not regulate repair of replication-induced DSBs. Representative images of chromosomes.

    Nature, 2017, 549(7673):548-552. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Clonogenic survival of cells expressing BARD1(WT)res or BARD1(AAE)res after treatment with olaparib or MMC. Data are means ± s.d., n = 3. EV, empty vector. P values were calculated using two-way ANOVA and multiple comparisons were corrected by the Bonferroni method. ** P < 0.01.

    Nature, 2017, 550(7676):360-365. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • a, IC50 levels of olaparib in EWS–FLI1 mutant cells (n = 17) versus breast cancers (n = 13) or pan-cancer (n = 147) dataset. b, Cell viability of IMR90 and Ewing sarcoma cells with increasing doses of olaparib. Mean ± s.d., n = 3 technical replicates, one-way ANOVA compared to IMR90 cells. c, Cell viability plot demonstrating the role of EWS–FLI1 in mediating exquisite sensitivity to olaparib in U2OS cells transfected with either the oncogene or empty vector; n = 3 transfection replicates.

    Nature, 2018, 555(7696):387-391. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Western blot analysis showing PARylated proteins in cells subject to the indicated PARP inhibitor treatments (5 μM Olaparib and 10 μM NU1025).

    Cell, 2018, 172(3):439-453. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    (A) Representative confocal microscopy images of nuclear γ-H2AX (red) and DAPI (blue) staining in FKO1 cells 30 minutes following irradiation. Cells pre-treated for 24hr with 1μM NanoOlaparib, olaparib, or a vehicle control before irradiation.

    Mol Cancer Ther, 2017, 16(7):1279-1289. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXROEBl NILnNYVKSzVyPUWuO|A2KCEQvF2g NVnQO5VzOTh3NUm2NVM>
KP6.3 MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUC0JIQ> NVXCbZZSUUN3ME2xNE41OjhizszNJC=> NEH4cWsyQDV3OU[xNy=>
KP7.7 MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[0JIQ> MV;JR|UxRTV5IH7NJC=> NYXxc493OTh3NUm2NVM>
KB2P3.4 NU\h[WtQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\3S|Qh\A>? MlHMTWM2OD1zMkSgUUA> MkfJNVg2PTl4MUO=
KB2P1.21 NYDGSItrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYi0JIQ> MmfUTWM2OD16OUC3JI5OKA>? MkHsNVg2PTl4MUO=
U373-MG MV;DfZRwfG:6aXOgRZN{[Xl? NWrUT|VHOSEQvF2g MnvYNlQhcA>? NGTYd3hKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 M3\p[VE5QTV2N{Gy
T98G M{jtO2N6fG:2b4jpZ{BCe3OjeR?= NVTyZ2lMOSEQvF2g M1q0Z|I1KGh? NGD3Z4VKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 MXmxPFk2PDdzMh?=
U87-MG MX7DfZRwfG:6aXOgRZN{[Xl? M2HuSFEh|ryPIB?= NEL0fIgzPCCq NH3B[|hKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 NUTjRm5IOTh7NUS3NVI>
UVW MV;DfZRwfG:6aXOgRZN{[Xl? NFHEV5c2ODBibl2= NIezOXgzPCCq NWDl[5o2UW6lcnXhd4V{KHKjZHnheIlwdiC|ZX7zbZRqfmm2eR?= Mnr2NVg6PTR5MUK=
HeLa M4i4fWZ2dmO2aX;uJGF{e2G7 M{C5VlUxOCCwTR?= NXTRRpJCPCCq M2nDNmNifXOnczDhJI1w\GW|dDDk[YxigSCrbjDy[YpwcW6rbnegc4YhemGmaXH0bY9vNWmwZIXj[YQhTE6DIHLy[YFsew>? MW[xPFk2PDdzMh?=
HeLa M2fPVGZ2dmO2aX;uJGF{e2G7 NYmyTnVPOSEQvF2g MV2yOEBp M1;3S2VvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJHMueGijc3WgZZJz\XO2 NEnVOFAyQDl3NEexNi=>
T98G MnjuSpVv[3Srb36gRZN{[Xl? NU\5XIxXOSEQvF2g M{PMNVI1KGh? MonYSY5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgV{1xcGG|ZTDhdpJme3R? NEDpRnUyQDl3NEexNi=>
L3 MmizR5l1d3SxeHnjJGF{e2G7 M1fiO|Uh|ryPIB?= NFLJ[mg6PiCq M1PCS2ROW09? M1G2ZnNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=> MkjJNlAyOjR2NUm=
Granta-519 M{DiTGN6fG:2b4jpZ{BCe3OjeR?= MWe1JO69VSB? MX25OkBp M3\ufmROW09? NVXzemdvW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= MnPkNlAyOjR2NUm=
BT NISw[5hEgXSxdH;4bYMhSXO|YYm= Mnf0OUDPxE1i MlLLPVYhcA>? MYHEUXNQ NFG1NW1UdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu M3fDZ|IxOTJ2NEW5
UPN2 NF7QRZlEgXSxdH;4bYMhSXO|YYm= MUK1JO69VSB? NGjnUGU6PiCq M1zTd2ROW09? NUHZUI5iW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= M2e5UlIxOTJ2NEW5
HBL-2 MWnDfZRwfG:6aXOgRZN{[Xl? MkLSOUDPxE1i NEX5SYk6PiCq MYPEUXNQ MUXTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt MUGyNFEzPDR3OR?=
JVM-2 M33DR2N6fG:2b4jpZ{BCe3OjeR?= M2rMXFUh|ryPIB?= NFPQb246PiCq MWDEUXNQ MXzTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt NXmxc|FFOjBzMkS0OVk>
Z138 MVXDfZRwfG:6aXOgRZN{[Xl? NIXDZnc2KM7:TTC= NGXqZ5M6PiCq MWPEUXNQ MmDtV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? MkTQNlAyOjR2NUm=
RWPE MlPpTY53[XOrdnWgRZN{[Xl? M3:5[lI2KM7:TR?= MkC5OFghcA>? M3vRfWROW09? M1vEXXNq\26rZnnjZY51dHlicnXkeYNmeyCHUlet[JJqfmWwIHPlcIwhcW64YYPpc44> M4TqSFIyPTd3OE[1
VCaP M{TLSWlvfmG|aY\lJGF{e2G7 MkDmNlUh|ryP M3;lcVQ5KGh? M3TK[2ROW09? NEjYNlhUcWewaX\pZ4FvfGy7IILl[JVk\XNiRWLHMYRzcX[nbjDj[YxtKGmwdnHzbY9v MlPVNlE2PzV6NkW=
Mouse H2AX−/− ES Cells NXfVRVRGS3m2b4TvfIlkKEG|c3H5 Mo\YNk42KM7:TR?= MWmyNEBp NGjwTpBUcWewaX\pZ4FvfGy7IHnubIljcXS|IHPlcIwhe3W{dnn2ZYw> M2f4XFI{OzV3NEi5
Mouse ATM−/− ES Cells NWr4fWJ5S3m2b4TvfIlkKEG|c3H5 NFPmU4ozNjVizszN M3r3SFIxKGh? M1jDbHNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=> Ml;MNlM{PTV2OEm=
H1650 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV63UpdXOjBizszN NUe2[JNQOTR2IHi= MlXkTWM2OD1zNT60O{DPxE1? NVzmN|ROOjN{M{m4NFk>
H1650PTEN+ NWfmbFVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fmXlIxKM7:TR?= NVPqSndlOTR2IHi= NEHxcXRKSzVyPUWwMlg{KM7:TR?= M3\Db|I{OjN7OEC5
PC-9 MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTCNlAh|ryP NYn4fZRVOTR2IHi= NV\0PZdnUUN3ME21Mlg5KM7:TR?= NEnhco4zOzJ|OUiwPS=>
PC-9PTEN− NVXjNGdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LaTlIxKM7:TR?= MX2xOFQhcA>? MYPJR|UxRTZwNUKg{txO M17LRlI{OjN7OEC5
MDA-MB-231 NV;4XXl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLUO2I2KGSjeR?= M4HXN2lEPTB;Nj65JO69VQ>? Mk\INlM4PjB2OU[=
MDA-MB-468 MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HvZ|Uh\GG7 NEjLW2FKSzVyPUWuNEDPxE1? M1PlTlI{PzZyNEm2
BT20 MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHz0eJI2KGSjeR?= NX3rUnRVUUN3ME23Mlch|ryP Mm\BNlM4PjB2OU[=
HCC1143 NH\1U3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXy1JIRigQ>? MXXJR|UxRTFzLkGg{txO NWHOVIZoOjN5NkC0PVY>
HCC1937 NFrFUHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS4OUBl[Xl? MW\JR|UxRTF{Lk[g{txO NFTUVVYzOzd4MES5Oi=>
Hs578t M{j6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC5W4FyPSCmYYm= NXvOOW81UUN3ME21MlYh|ryP NFvXTGUzOzd4MES5Oi=>
Hs578t(si) MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;Y[4Y2KGSjeR?= MV3JR|UxRTdwNTFOwG0> NX[yeotKOjN5NkC0PVY>
BT474 M{jmO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHjUGczPSCmYYm= NF;KPXRKSzVyPUG5Mlgh|ryP NUiwd5NkOjN5NkC0PVY>
JIMT1 NW[2fGRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zzc|Uh\GG7 NH2yVXRKSzVyPUeuO{DPxE1? MlvaNlM4PjB2OU[=
SKBR3 NWW5SJZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DrcFUh\GG7 MWTJR|UxRTFzLkGg{txO NVvmSHlGOjN5NkC0PVY>
SUM159 MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzpe|Q2KGSjeR?= MXjJR|UxRTRwMjFOwG0> MmDYNlM4PjB2OU[=
CAMA1 NHi1S|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV21JIRigQ>? M1:wT2lEPTB;MUWuPEDPxE1? MnrmNlM4PjB2OU[=
MCF7 NUOzZnkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXO1JIRigQ>? MkTyTWM2OD13Lkig{txO MonGNlM4PjB2OU[=
T47D M3i0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfqbno2PSCmYYm= M{ntOWlEPTB;OT62JO69VQ>? M{jORlI{PzZyNEm2
HCT116 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELXb4syODBizszN MVG0PEBp Mn7TSG1UVw>? MorVTWM2OD1{LkWg{txOKA>? NWf0eoRMOjR3N{e5OFE>
SW1116 M3vxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKxNFAh|ryP Mn[5OFghcA>? NX3zT255TE2VTx?= NGLw[5hKSzVyPUGwNEDPxE1? M3nSe|I1PTd5OUSx
HT29 NUDZU4FWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PsTlExOCEQvF2= NHzSd4E1QCCq MWHEUXNQ MmG1TWM2OD1zND63JO69VQ>? NX6y[m14OjR3N{e5OFE>
LoVo M2\me2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkD0NVAxKM7:TR?= NVL0ZlRuPDhiaB?= MkDuSG1UVw>? M1f5d2lEPTB;MUOuOEDPxE1? M1HsblI1PTd5OUSx
HCT-15 NIrnUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jTSVExOCEQvF2= M{m4TVQ5KGh? MlX5SG1UVw>? M4D6c2lEPTB;MUCg{txO NXHvfIV3OjR3N{e5OFE>
SW48 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrlNVAxKM7:TR?= NVLPeYNkPDhiaB?= NWfBSo0zTE2VTx?= NX;JW45yUUN3ME25MlUh|ryP M3LFWlI1PTd5OUSx
C-1 NWD6fXoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvrSXo4OTByIN88US=> NVjKTZhnPDhiaB?= NVP3PXlxTE2VTx?= MUTJR|UxRTdwNjFOwG0> M3LyU|I1PTd5OUSx
RKO NVfnNHUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGxNFAh|ryP NE\abm01QCCq NGnSO3ZFVVOR NHjJfnhKSzVyPUWuPUDPxE1? M1HIblI1PTd5OUSx
HCT116 NVrJR4ROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:xNFAh|ryP NYDOW45RPDhiaB?= NILpOYlFVVOR NXfuUHlpWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= NH;EWIczPDV5N{m0NS=>
SW1116 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfyW|UyODBizszN NEXzNXY1QCCq MVLEUXNQ NFi5OW5Rd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli NFS4bnczPDV5N{m0NS=>
HT29 NHjWc2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYSxNFAh|ryP NUTDTmhtPDhiaB?= MYPEUXNQ M3uxZnBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? M1nWblI1PTd5OUSx
LoVo NIn4PWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[xNFAh|ryP NXK0WYdpPDhiaB?= MkXTSG1UVw>? NWC0fotUWG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= Mnn1NlQ2Pzd7NEG=
SW48 NGXiToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzDNVAxKM7:TR?= NIr6WlM1QCCq MXvEUXNQ M3z1[XBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? NFrqWmszPDV5N{m0NS=>
C-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljjNVAxKM7:TR?= NEXHZoE1QCCq NWfGcY5JTE2VTx?= M3;1WXBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? NGfPSZczPDV5N{m0NS=>
RKO M175TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC5NVAxKM7:TR?= NVzjTW1MPDhiaB?= MnjXSG1UVw>? NGC2[|lRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli MmjuNlQ2Pzd7NEG=
HCT116 NY\McoNpTnWwY4Tpc44hSXO|YYm= NUm0TYg2OTBibl2= M3zURlEzKGh? M3HnW2ROW09? NVTaNIN6UW6lcnXhd4V{KESQQTDkc5VjdGVvc4TyZY5lKGK{ZXHrd{BqdmS3Y3XkJIJ6KFOQLUO4 MUeyOFU4Pzl2MR?=
HT29 NHz0RoNHfW6ldHnvckBCe3OjeR?= M{Cwe|ExKG6P NIXsclUyOiCq M1HhfWROW09? MXXJcoNz\WG|ZYOgSG5CKGSxdXLs[U1{fHKjbnSgZpJm[Wu|IHnu[JVk\WRiYomgV24uOzh? NYXqXGFlOjR3N{e5OFE>
TE-6 NFzDdZNHfW6ldHnvckBCe3OjeR?= MkfiOUDPxE1i MYWxNkBp MlvSSG1UVw>? M33Zbmlv\HWlZYOgS|IwVSCjcoLld5Q> NVTXNHlUOjR{MUmxOlQ>
TE-6 NHr4RnVHfW6ldHnvckBCe3OjeR?= MXG1JO69VSB? NYfnXlZjOjRiaB?= Mme1SG1UVw>? MWLJcoNz\WG|ZYOgbY4h\G:3YnzlJJN1emGwZDDidoVic3NiKFTTRpMq NYXQ[|BjOjR{MUmxOlQ>
Hep3B NV36fnM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XVflQxKM7:TTC= NGWyW2E4OiCq NECybmdFVVOR NXuwbXNvW3mwZYLnbZN1cWOjbHz5JIlvcGmkaYTzJINmdGxiZ4Lve5RpKHerdHigSGhOTVF? M1PjOlI2ODd{N{Wy
Huh7 NFjySG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne3OFAh|ryPIB?= NFf6d3o4OiCq MXPEUXNQ NIfjfZNUgW6ncnfpd5Rq[2GubImgbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2m2aDDETG1GWQ>? M1nT[VI2ODd{N{Wy
Hep3B NVfWfJFMTnWwY4Tpc44hSXO|YYm= M{\SVlQxKM7:TTC= NUCyVYdnOjRiaB?= NELwd3ZFVVOR M4rOWGlv\HWlZYOgVm9UKHC{b3T1Z5Rqd25id3n0bEBFUE2HUR?= M2DTfVI2ODd{N{Wy
Huh7 Mn6ySpVv[3Srb36gRZN{[Xl? NHzkRXU1OCEQvF2g MX6yOEBp MXvEUXNQ MnfHTY5lfWOnczDSU3MheHKxZIXjeIlwdiC5aYToJGRJVUWT M{nt[lI2ODd{N{Wy
Hep3B MlvmSpVv[3Srb36gRZN{[Xl? NUPBO|NJPDBizszNJC=> Mn;MNlQhcA>? NVzpSpFITE2VTx?= NILBTWdKdmS3Y3XzJINmdGxiYYX0c5Bp[We7IIfpeIghTEiPRWG= NHLaXpozPTB5Mke1Ni=>
Huh7 NHPpRW9HfW6ldHnvckBCe3OjeR?= MUi0NEDPxE1i NILyVnYzPCCq Ml70SG1UVw>? NHXzcFRKdmS3Y3XzJINmdGxiYYX0c5Bp[We7IIfpeIghTEiPRWG= NWL3TZJVOjVyN{K3OVI>
SGC-7901 NI\FTFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7NU20{OMLizszN NX;4OnNTPDhiaB?= NEPVUm5FVVOR MkfjRoxw[2tib4jhcIlxdGG2aX6tbY5lfWOnZDDj[YxtKGSnYYTo M4LzR|I2PzZ5MEe2
COLO-800 MknUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwNESxOlQh|ryP NVnVZ|VqW0GQR1XS
EoL-1- M1niN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\xO2lEPTB;MD61OlQ1PiEQvF2= NE\tWIhUSU6JRWK=
NCI-H209 NWHWemx5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC0Znp4UUN3ME2wMlkyPTV4IN88US=> MUnTRW5ITVJ?
ES1 M2nBOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17UZmlEPTB;MT6xNVQxQCEQvF2= Mm\HV2FPT0WU
NKM-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHvfm5KSzVyPUGuNlU{PDdizszN MYHTRW5ITVJ?
NTERA-S-cl-D1 MoPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjscJJuUUN3ME2xMlM{OzRzIN88US=> NVLq[nlnW0GQR1XS
MHH-ES-1 M1zTWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\Nd2lKSzVyPUGuOlIxPjdizszN MX\TRW5ITVJ?
ES8 NH3pVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33pO2lEPTB;MT63NlQyPCEQvF2= MlTPV2FPT0WU
NCI-H720 NE\Wc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJwMkC2PVkh|ryP MlXSV2FPT0WU
EW-3 NHTqSHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPFN4VbUUN3ME2yMlI4PTN2IN88US=> NEDCR|RUSU6JRWK=
D-566MG M4Tk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;lTWM2OD1{LkS0OVY5KM7:TR?= M3vSe3NCVkeHUh?=
697 M{DsWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnFbo5sUUN3ME2yMlg1OTd|IN88US=> NFfrWJVUSU6JRWK=
ES5 NFnCTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LWUWlEPTB;Mj64PFE5QSEQvF2= NWO3XoNMW0GQR1XS
COLO-684 M1\rV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTNwNUG2PVYh|ryP NF;aOlBUSU6JRWK=
ML-2 MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DlSGlEPTB;Mz62NFA2QCEQvF2= MnqyV2FPT0WU
MC-IXC MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[xd3BKSzVyPUOuOlM{QTNizszN M3\SOXNCVkeHUh?=
DB Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzRTWM2OD1|Lk[1OFQ5KM7:TR?= MWnTRW5ITVJ?
HCC2218 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:yTWM2OD1|LkezNVA{KM7:TR?= Mnu0V2FPT0WU
NCI-H510A MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTNwOEK3NlQh|ryP MX\TRW5ITVJ?
NCI-H526 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTNwOE[5OVgh|ryP Mn;ZV2FPT0WU
MV-4-11 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7BPHdKSzVyPUSuNVM{OzRizszN MUHTRW5ITVJ?
PA-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TTUWlEPTB;ND6yOVI6KM7:TR?= Mmn3V2FPT0WU
EW-22 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHe2SIZKSzVyPUSuN|U5PiEQvF2= NIi5UGJUSU6JRWK=
KASUMI-1 MoHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\jTWlEPTB;ND60NFExQSEQvF2= NGH5UI9USU6JRWK=
LU-139 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTRwN{W4Nlkh|ryP NV\oRWF[W0GQR1XS
SBC-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTRwOEC5NFgh|ryP MkjSV2FPT0WU
H4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTM[4hKSzVyPUSuPFk1PDNizszN MXzTRW5ITVJ?
EW-11 MnTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofxTWM2OD13LkC4NFczKM7:TR?= NWKyN2ZPW0GQR1XS
NBsusSR NFnwUohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTVwMUKwOVUh|ryP NHL5OnFUSU6JRWK=
RPMI-8226 NUn1VYYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfsTWM2OD13LkG1NlQ1KM7:TR?= NI\aNlFUSU6JRWK=
DEL MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\rZlNKSzVyPUWuNlAxODZizszN NVHGfFNRW0GQR1XS
ES4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fGcWlEPTB;NT61NVM5QSEQvF2= M{LNdHNCVkeHUh?=
GCT M3LYUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vRfWlEPTB;NT61Olg2PiEQvF2= NFKwR5BUSU6JRWK=
NCI-H1048 Mn3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2n1TWlEPTB;NT65O|I4OyEQvF2= MoTpV2FPT0WU
NCI-SNU-1 NVzLc49XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fCUGlEPTB;Nj6wNlIh|ryP MlnaV2FPT0WU
ES7 NVXBZYc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPVbpdiUUN3ME22MlA{PTd5IN88US=> MVzTRW5ITVJ?
SW982 MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTZwMEmxN|ch|ryP NV;TOXRoW0GQR1XS
L-363 NXn4VFlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEW3dFBKSzVyPU[uN|M6PzRizszN M4H5eXNCVkeHUh?=
HT-1080 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDVWXkzUUN3ME22MlQ6Pjh|IN88US=> MUnTRW5ITVJ?
HAL-01 M{G4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjGUJIyUUN3ME22MlUyODlizszN M4rnNnNCVkeHUh?=
NB14 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUG3N3ppUUN3ME22MlY1ODN7IN88US=> NUjRb3Z6W0GQR1XS
EW-13 M4P2cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYq0O4d4UUN3ME22Mlc4PDJ2IN88US=> NHnDfoFUSU6JRWK=
NY NXzmd3lyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTZwOUS2NFUh|ryP MVHTRW5ITVJ?
NCI-SNU-5 M{C3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Hw[2lEPTB;Nz6xNFQ{OyEQvF2= MmG4V2FPT0WU
MS-1 M4HqPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLTTWM2OD15LkG3OFk1KM7:TR?= MkTNV2FPT0WU
EW-16 M4rGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zYXmlEPTB;Nz6zNVg3OSEQvF2= M1fGfXNCVkeHUh?=
LU-65 NF[yW3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu4UIlKSzVyPUeuOFg1OTdizszN NVr5W|ZFW0GQR1XS
HGC-27 NHj2W25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLufXBWUUN3ME23MlczOTd|IN88US=> NV7MNIJvW0GQR1XS
CTB-1 M2DZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHUc3NKSzVyPUeuO|YyPzVizszN Ml35V2FPT0WU
5637 NVrLb4Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TMS2lEPTB;Nz65Nlg3KM7:TR?= NFLXU3RUSU6JRWK=
U251 MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXSXXg2UUN3ME23Mlk1ODF4IN88US=> MkHnV2FPT0WU
HOS MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLp[VRKSzVyPUiuNlMxODdizszN MXHTRW5ITVJ?
DOHH-2 M3:5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRThwMkO1PEDPxE1? M3;BS3NCVkeHUh?=
EW-1 M2XPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr1TWM2OD16LkOwNFg5KM7:TR?= NVrTTGtCW0GQR1XS
BV-173 NGrDTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLZTWM2OD16LkW1OVQh|ryP NGHBdWZUSU6JRWK=
8-MG-BA MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEL5V4VKSzVyPUiuOlg6QDhizszN M{\LbHNCVkeHUh?=
NB69 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XDbmlEPTB;OD63NFkzOSEQvF2= M1rJNnNCVkeHUh?=
NCI-H69 MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEL0V|hKSzVyPUmuPVA6PjFizszN NE\henlUSU6JRWK=
RS4-11 M4HhPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHWe4pKSzVyPUGxMlIzODhizszN MoHLV2FPT0WU
ONS-76 NHnle3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PwN2lEPTB;MUGuNlk1PyEQvF2= M4DTNHNCVkeHUh?=
SF539 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPXXWhKSzVyPUGxMlQ5QDlizszN Mn;HV2FPT0WU
HuO-3N1 NIHKZlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTiR4hKSzVyPUGxMlU4QTZizszN NGfhS4xUSU6JRWK=
NCI-H1651 MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH3TWM2OD1zMj6zNVE2KM7:TR?= MUHTRW5ITVJ?
KARPAS-45 NEfHb4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfTO2lKSzVyPUGyMlM4PiEQvF2= NUHTRpVPW0GQR1XS
SK-NEP-1 NWTVOIVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{WzTGlEPTB;MUKuOFYxQSEQvF2= NGrtZVZUSU6JRWK=
LAMA-84 NI\aXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXm1dZR4UUN3ME2xN{4yODl3IN88US=> NXT5eZB7W0GQR1XS
NCI-H1155 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XFSmlEPTB;MUOuNlg2PiEQvF2= MlvGV2FPT0WU
CTV-1 NEjDfodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M374cmlEPTB;MUOuOFQ2KM7:TR?= NH22dFRUSU6JRWK=
QIMR-WIL M1HvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrXUG1IUUN3ME2xN{44QDF2IN88US=> M16zWnNCVkeHUh?=
H9 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjJWmhKSzVyPUGzMlg1PzVizszN NX;qSYUyW0GQR1XS
SK-MEL-1 NGjBXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;2PY9KSzVyPUGzMlk{PDdizszN Ml;rV2FPT0WU
HD-MY-Z NYr1Rnp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HLPWlEPTB;MUSuNFY{PyEQvF2= MmH4V2FPT0WU
TI-73 M3Tid2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF2LkKzOVYh|ryP M{PESnNCVkeHUh?=
JVM-3 M3L3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzKRYRKSzVyPUG1MlU4OTZizszN MWPTRW5ITVJ?
D-247MG NXvCZ2kyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXW2TYpMUUN3ME2xOU42QTNizszN MnyxV2FPT0WU
VA-ES-BJ MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vUbGlEPTB;MUWuOlA6PyEQvF2= NGT2dW5USU6JRWK=
NOS-1 NYW3RWhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHe4fYFKSzVyPUG1MlY2OjJizszN Mo\SV2FPT0WU
MOLT-4 M4W1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq1OHdlUUN3ME2xOk44PTJizszN MlHBV2FPT0WU
Mo-T Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTBTWM2OD1zNz6wPFQ6KM7:TR?= Ml7mV2FPT0WU
NCI-H1770 NXfKPY5sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHFT2ptUUN3ME2xO{4yPTR|IN88US=> NWfnd3FFW0GQR1XS
COLO-320-HSR MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoiyTWM2OD1zNz6xPFI4KM7:TR?= M1jab3NCVkeHUh?=
TE-12 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLzN2lKSzVyPUG3MlcxPTRizszN NVvO[Ww2W0GQR1XS
NCI-H82 NVLBTJczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml33TWM2OD1zNz64O|I5KM7:TR?= M1PPdnNCVkeHUh?=
NEC8 NYixfHdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFexdmZKSzVyPUG4MlE{OTZizszN NYnNR25UW0GQR1XS
HSC-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jjWmlEPTB;MUiuO|QyPCEQvF2= MU\TRW5ITVJ?
NCI-H1092 MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonKTWM2OD1zOD63OVk2KM7:TR?= MVTTRW5ITVJ?
NCI-H292 Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILIN2tKSzVyPUG5MlA1QDlizszN M4DLOHNCVkeHUh?=
L-428 NE\2bJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDwTZVKSzVyPUG5MlU2QSEQvF2= M163V3NCVkeHUh?=
LU-134-A NFHqfWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4GzOmlEPTB;MUmuOVczKM7:TR?= M3vOenNCVkeHUh?=
GI-ME-N NVLRemxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvSOnRKSzVyPUG5MlU4PDdizszN MmfZV2FPT0WU
ALL-PO MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fXfWlEPTB;MUmuOVk4OiEQvF2= Mn\TV2FPT0WU
D-283MED NIfHZ4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjqb2tKSzVyPUG5MlkyPSEQvF2= NH\RTo1USU6JRWK=
D-423MG MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XQfGlEPTB;MUmuPVk3PyEQvF2= NXTzdVd4W0GQR1XS
CAKI-1 Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3aRnVKSzVyPUKwMlIzOTlizszN MYTTRW5ITVJ?
ETK-1 NYTXOGw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3OTWM2OD1{MD6yOlE2KM7:TR?= NVzycXFKW0GQR1XS
G-402 NXLFR21VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\wWldKSzVyPUKwMlU{OzRizszN M4[yNnNCVkeHUh?=
HL-60 NWLHSGxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJzLkG2NVMh|ryP NHzBXZVUSU6JRWK=
A2058 M4T0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDMPFBDUUN3ME2yNU41PDd5IN88US=> M{flc3NCVkeHUh?=
CHP-212 NG\J[|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJzLkmwOVEh|ryP MonVV2FPT0WU
KY821 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPCTWM2OD1{MT65O|Uh|ryP M2DUc3NCVkeHUh?=
TYK-nu MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIn2OolKSzVyPUKyMlA3PTFizszN NX3xOG9YW0GQR1XS
JVM-2 M4LPOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:xeWlEPTB;MkKuNlk5OyEQvF2= MUDTRW5ITVJ?
KU812 NIn5dJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{W0SGlEPTB;MkKuO|MyOiEQvF2= NU[5fJB7W0GQR1XS
MKN28 NHiyd2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPEfmlKSzVyPUKyMlkxOTVizszN MY\TRW5ITVJ?
ECC10 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7GblExUUN3ME2yN{44PDFizszN NWLtcpV4W0GQR1XS
BHT-101 NFvrOYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf6UHpKSzVyPUK0MlAxODhizszN Mkj0V2FPT0WU
DU-4475 NFO2e5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJ2LkOzN|ch|ryP MXTTRW5ITVJ?
769-P NVzpVXN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nDcmlEPTB;MkSuPFQ3PiEQvF2= MUTTRW5ITVJ?
HEC-1 MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MormTWM2OD1{NT60OFUh|ryP MXvTRW5ITVJ?
MOLT-13 M1npZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInEXmlKSzVyPUK1MlU{OzFizszN MnjXV2FPT0WU
8505C NV7rfm4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDIe3FKSzVyPUK2MlQ6PzdizszN NFu0bm1USU6JRWK=
GB-1 NUjRdGxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTJ4LkexO|Yh|ryP M1XEW3NCVkeHUh?=
SF126 NXnnRmRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnRSJpKSzVyPUK2Mlc3PDhizszN NHnjRYlUSU6JRWK=
A4-Fuk NYrvR4JiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\PWmNYUUN3ME2yO{4yOjdzIN88US=> MXzTRW5ITVJ?
OVCAR-8 NIK0XldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDiTWM2OD1{Nz6xOVM6KM7:TR?= NXnxbGFZW0GQR1XS
NCI-H1304 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{KxfWlEPTB;MkeuOVQh|ryP NIPCOIRUSU6JRWK=
GR-ST NV63cIFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrJd|ZKSzVyPUK4MlA1PyEQvF2= M4qwdnNCVkeHUh?=
G-401 NHXv[lNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfkSXNKSzVyPUK4MlUxQTZizszN NG\PcFdUSU6JRWK=
LXF-289 M2HrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTPSYl{UUN3ME2yPE42PjVzIN88US=> NYDTTJNMW0GQR1XS
DBTRG-05MG Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ6LkmyNFQh|ryP Ml3TV2FPT0WU
YKG-1 M3W3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXZPJpKSzVyPUK5Mlg3QCEQvF2= MofNV2FPT0WU
GAMG NX\Y[JkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{noNGlEPTB;MkmuPVk{KM7:TR?= NUnCO|lPW0GQR1XS
HCT-116 M4PUW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPxbnNKSzVyPUOwMlA2PDhizszN MVXTRW5ITVJ?
S-117 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnIcYNKSzVyPUOxMlIzPTdizszN NYf0d2dzW0GQR1XS
NCI-H1693 MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jtc2lEPTB;M{OuOlU1OiEQvF2= NIHZcVlUSU6JRWK=
A427 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPQTWM2OD1|Mz65PVc3KM7:TR?= MWTTRW5ITVJ?
HT-29 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3W2OGlEPTB;M{SuOlA{OiEQvF2= NULLbIYyW0GQR1XS
P12-ICHIKAWA MnrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWflTmV1UUN3ME2zOE44PDlzIN88US=> MWTTRW5ITVJ?
CAL-51 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXwc4VKSzVyPUO1MlA4ODlizszN NFThZ2hUSU6JRWK=
Ramos-2G6-4C10 NF3kT4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHK2O3pKSzVyPUO1MlI1OjVizszN NHvD[ZFUSU6JRWK=
SCH MkHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHQTWM2OD1|Nj60NVc1KM7:TR?= NYr2cFVmW0GQR1XS
SK-MEL-24 NYnq[IdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\GTWM2OD1|Nj65NFQ1KM7:TR?= M{jCOnNCVkeHUh?=
SW1573 NUnsR4RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fPZ2lEPTB;M{iuO|IyPiEQvF2= MmjtV2FPT0WU
BALL-1 MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrGU4xyUUN3ME2zPU4zOTJ7IN88US=> MVPTRW5ITVJ?
BE-13 MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LB[WlEPTB;M{muN|I6KM7:TR?= NFSxVYNUSU6JRWK=
GI-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXSTWM2OD1|OT64OlQ4KM7:TR?= MUDTRW5ITVJ?
GOTO MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37qRmlEPTB;M{muPVE{QSEQvF2= NIjOR3RUSU6JRWK=
A673 M{jpc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGT1U4tKSzVyPUSxMlA{PDNizszN NWS4eWxLW0GQR1XS
KG-1 NYn3eI1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTZ[oQ2UUN3ME20N{4{QTRizszN MUXTRW5ITVJ?
GP5d M{\MSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDlOmlKSzVyPUS0MlA3PjZizszN MnjwV2FPT0WU
MFM-223 M2PmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrlTWM2OD12ND6xNlI5KM7:TR?= M3GyPHNCVkeHUh?=
OAW-42 MkjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD5ZWx{UUN3ME20OE4zPjR|IN88US=> NIr1fIFUSU6JRWK=
C8166 Mnm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fVWmlEPTB;NEWuNFgzOiEQvF2= NYjtR5hkW0GQR1XS
LU-99A MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTR4LkGzNlIh|ryP M2[1bHNCVkeHUh?=
NCI-H23 NX;QZZpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;GTWM2OD12Nj6xO|g2KM7:TR?= NFz2OYhUSU6JRWK=
HO-1-N-1 NYHsWI8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTR5LkC5PVgh|ryP MXHTRW5ITVJ?
A3-KAW M4HlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXFVYZHUUN3ME20O{4yODB5IN88US=> NHrD[5dUSU6JRWK=
CGTH-W-1 M1PhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTR5LkWwOlkh|ryP M4fmVnNCVkeHUh?=
DJM-1 NFP0O2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTR5LkW0NVMh|ryP MlvRV2FPT0WU
A101D M2iwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTR5Lk[zOVch|ryP MlfJV2FPT0WU
BB30-HNC MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnDZmlKSzVyPUS4MlMxPzJizszN NGTLV49USU6JRWK=
T98G Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVz0bldSUUN3ME20PE41PjN|IN88US=> NXLFWJRbW0GQR1XS
NCI-H1573 NIflZpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MomxTWM2OD12OT60OFYzKM7:TR?= MoXrV2FPT0WU
MEG-01 NF7KcWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTR7Lke0NVEh|ryP NV\oN2NlW0GQR1XS
WM-115 MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\SVpJKSzVyPUS5MlkzOjJizszN NFXDTWFUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay:

[1]

+ Expand

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research:

[1]

+ Expand
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01758731 Active, not recruiting Squamous Cell Carcinoma of the Head and Neck University of Colorado, Denver July 9, 2012 Phase 1
NCT02484404 Recruiting Lung Cancer|Breast Cancer|Ovarian Cancer|Colorectal Cancer|Prostate Cancer|Triple Negative Breast Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) June 4, 2015 Phase 1|Phase 2
NCT02769962 Recruiting Solid Tumors|Small Cell Lung Carcinoma|Carcinoma, Non-Small-Cell Lung|Lung Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) May 3, 2016 Phase 1|Phase 2
NCT01237067 Completed Cervical Cancer|Ovarian Cancer|Breast Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer|Endometrial Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2010 Phase 1
NCT00678132 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 24, 2008 Phase 1
NCT02121990 Active, not recruiting Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer Memorial Sloan Kettering Cancer Center|AstraZeneca|Genentech, Inc. April 21, 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • Answer:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • Question 2:

    How long can the chemical compound be stable in DMEM at 4 ℃?

  • Answer:

    The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) supplier | purchase Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) cost | Olaparib (AZD2281, Ku-0059436) manufacturer | order Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID